INTRODUCTION AND OBJECTIVES: Following the results of the TOPARP-A Phase II trial, Olaparib, an oral PARP inhibitor was recently recognized as a FDA breakthrough therapy for metastatic castration recurrent prostate cancer (mCRPC) patients who have germline mutations in DNA repair genes. Although these results are noteworthy, the problem remains of how to treat the remaining mCRPC patients who do not have detectable germline mutations of DNA repair genes. Androgen receptor (AR) signaling regulates DNA repair in prostate cancer and AR modulating drugs induce DNA damage. Thus a combination approach using AR modulating drugs with a PARP inhibitor could be a promising option for the treatment of mCRPC. All currently approved AR modulating drugs, such as enzalutamide and abiraterone, either directly or indirectly target the AR C-terminus ligand-binding domain (LBD). Such drugs are often unsuccessful due to the emergence of AR splice variants (ARV-7, ARv567es) that are constitutively active and lack a LBD. EPI-002 is a first-in-class AR antagonist that targets both full-length AR and AR splice variants. Here we present data to support that a combination of Olaparib, a PARP inhibitor, and EPI-002 have beneficial effects in vitro.
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METHODS: Combination therapy using EPI-002 and Olaparib were evaluated in vitro using human prostate cancer cells, LNCaP (androgen sensitive and expresses full-length AR) and LNCaP95, an androgen-independent cell line that expresses full-length AR and AR-V7 and is resistant to enzalutamide. The effects of monotherapy and combination therapy on cell cycle and DNA damage were analysed using FACS and Western blot.
RESULTS: Unexpectedly, EPI-002 caused an enormous decrease of Checkpoint kinase 1 (Chk1) protein levels in LNCaP and LNCaP95 cells. Chk1 is one of the important mediators in cell cycle checkpoint during the DNA damage response. Whereas, enzalutamide also decreased the expression of Chk1 in LNCaP, it had no effect on Chk1 levels in LNCaP95 cells. Consistent with these data, AR knockdown in LNCaP cells also decreased Chk1 levels. The PARP inhibitor, Olaparib, induced phosphorylation of Chk1. EPI-002 induced G1 cell cycle arrest whereas Olaparib induced G2/M cell cycle arrest. FACS analysis of gH2AX showed increased DNA damage with combination therapy compared to monotherapies.
CONCLUSIONS: EPI-002 decreased the expression of Chk1 in prostate cancer cells that expressed both full-length AR and AR-V7. Combination therapy of EPI-002 plus Olaparib may provide a therapeutic approach for prostate cancer that expresses AR-V7. 
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INTRODUCTION AND OBJECTIVES:
Multiple androgen receptor (AR) dependent and independent resistance mechanisms limit the efficacy of current castration resistant prostate cancer (CRPC) treatment modalities. EPI-001 is a novel N-terminal domain (NTD) binding AR targeting component with the promising ability to block constitutively active splice variants; a major resistance mechanism in CRPC. Autophagy a conserved lysosomal degradation pathway, is a survival mechanism in cells exposed to anti-cancer treatment. We hypothesized that also a promising NTD-AR treatment may lead to upregulation of autophagy, which can be targeted by a combination therapy with autophagy inhibitors.
METHODS: The human prostate cancer cell line LNCaP was cultured in steroid-free medium. Cells were treated with different concentrations of EPI-001 (10, 25, 50uM) and in combination with autophagy inhibitors chloroquine (CHQ, 20uM) or 3-methyladenine (3MA, 5mM). Viability was assessed by WST-1-assays after 1, 3 and 7 days. AnnexinV and Propidium Iodide were used to measure apoptosis and necrosis on day 7 after treatment. Autophagic activity was monitored on protein levels by western blot (WB) and immunocytochemistry for the expression of LC3-I/II, Atg5 and Beclin1. In addition, autophagosome increase was detected by Autodot staining.
RESULTS: Treatment with EPI-001 resulted in a dose dependent reduction of cell viability up to 50% with 50uM EPI-001 on day 7. At the same time apoptosis increased by 11.53% and necrosis by 3.74% compared to the control. Combination of 50 uM EPI-001 with autophagy inhibitors led to a further significant reduction of cell viability up to 40% for CHQ and 28% for 3MA. Assessment of autophagy levels in EPI-001 treated cells by WB showed an increase of LC3-II in a dose dependent manner. No Change in Beclin1 expression was seen. Immuncytochemistry detected a significant increase of Atg5 and pronounced LC3-II punctuation in EPI-001 treated cells. This was supported by an increase in autophagosome punctuation observed by Autodot staining.
CONCLUSIONS: Our data demonstrate that the treatment with EPI-001 leads to increased autophagic activity in LNCaP prostate cancer cells. Combination of N-terminal androgen receptor blockage with simultaneous autophagy inhibition increases the antitumor effect of EPI-001 in vitro. This may offer a promising strategy to overcome resistance mechanisms in castration resistant prostate cancer. 
The anti-diabetic drug metformin (MET) and the anti-epileptic drug sodium valproate (VPA), when used alone, have shown anti-cancer effects in prostate cancer (PCa). However high doses are required which results in unacceptable toxicity. Here, we aimed to determine if the combination of MET and VPA (MET+VPA) at clinically relevant doses would (1) induce a synergistic anti-tumor effect in human PCa cell lines and patient-derived PCa explants, (2) cause minimal toxicity to normal tissues in vivo, (3) identify prognostic molecular markers for MET+VPA responses and (4) lead to rapid clinical application.
METHODS: Human PCa cell lines (PC-3 and LNCaP) and radical prostatectomy explants from 8 patients were analyzed for response to MET+VPA. Ki67, cleaved caspase-3, the androgen receptor (AR), and p53 expression in explants were analyzed using immunohistochemistry. The combinatorial effects of MET+VPA were calculated using the Drug Combination Index (CI). The role of p53 and AR in response to MET+VPA was determined using TP53 gene knockdown in LNCaP and TP53 ectopic expression in PC3, and AR was chemically inhibited using Enzalutamide in LNCaP. The toxicity of MET+VPA was determined using histological scoring systems for kidney and liver toxicity in nude mice.
RESULTS: MET+VPA synergistically inhibited proliferation in both PC-3 and LNCaP and synergistically induced apoptosis in LNCaP cells (CI<0.9). All PCa explants (pathological stage pT2C-pT3A and e1108
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